학술논문
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Document Type
Article
Author
Rosenbaum, Evan; Chugh, Rashmi; Ryan, Christopher W.; Agulnik, Mark; Milhem, Mohammed M.; George, Suzanne; Jones, Robin L.; Chmielowski, Bartosz; Van Tine, Brian A.; Tawbi, Hussein; Elias, Anthony D.; Read, William L.; Budd, G. Thomas; Qin, Li-Xuan; Rodler, Eve T.; Hirman, Joe; Weiden, Paul; Bennett, Cathryn M.; Livingston, Philip O.; Ragupathi, Govind; Hansen, David; D'Angelo, Sandra P.; Tap, William D.; Schwartz, Gary K.; Maki, Robert G.; Carvajal, Richard D.
Source
In European Journal of Cancer November 2022 176:155-163
Subject
Language
ISSN
0959-8049